Justine J. Jacobi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Justine J. Jacobi has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Mark D. Long
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
71 shared publications - David W. Goodrich
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
49 shared publications - Eduardo Cortes Gomez
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
35 shared publications - Jianmin Wang
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
35 shared publications - Bo Xu
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications - Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
34 shared publications
Latest Publications
- 1 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (41) , 4442-4453
Neuromedin U ‘innervation’ reprograms myeloid immunosuppression in neuroendocrine prostate cancer
- 1 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (41) , 4442-4453
Neuromedin U ‘innervation’ reprograms myeloid immunosuppression in neuroendocrine prostate cancer
- Open Access
- 4 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Single-cell profiling uncovers a rare mesenchymal-like urothelial state associated with sarcomatoid bladder cancer
The bladder urothelium is a stratified epithelium, composed of basal, intermediate, and umbrella cells. While epithelial–mesenchymal transition is known to occur during bladder regeneration, carcinogenesis, and bladder cancer tumor progression, it remains unclear whether normal urothelial cells intrinsically possess a hybrid mesenchymal-like epithelial state. We analyzed scRNA-seq data of EPCAM+ urothelial cells from both mouse and human urothelium. Here, we identified and characterized a rare population of mesenchymal-like urothelial cells, termed M-cells, representing approximately 1–3% of urothelial cells. Vimentin-positive cells were evaluated by immunostaining to determine their distribution of M-cells in normal urothelial layers. M-cells are enriched within the basal layer but are present across all urothelial compartments. M-cells co-express epithelial markers with mesenchymal and stemness genes and engage stem cell-associated transcriptional regulators. Lineage tracing with the Upk2-Cre ; mT/mG reporter mice confirmed their urothelial origin, excluding a fibroblast lineage. M-cells exhibit high transcriptional plasticity between basal cells and intermediate cells. In addition, we identified a 16-gene transcriptional signature uniquely expressed in M-cells but absent in fibroblasts. RNA deconvolution of MB49 tumors demonstrated strong enrichment of M-cell signature, suggesting that MB49 tumors are more likely to represent sarcomatoid urothelial carcinoma rather than fibroblast-derived sarcoma. The clinical relevance of the M-cell state was validated in primary human sarcomatoid bladder cancer tumors and their corresponding patient-derived xenografts. Together, these findings establish rare and transcriptionally unique M-cells within the normal urothelium as a novel highly plastic population with clinical implications for both mouse and human sarcomatoid urothelial carcinoma.
- 4 August 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessSingle-cell profiling uncovers a rare mesenchymal-like urothelial state associated with sarcomatoid bladder cancer
The bladder urothelium is a stratified epithelium, composed of basal, intermediate, and umbrella cells. While epithelial–mesenchymal transition is known to occur during bladder regeneration, carcinogenesis, and bladder cancer tumor progression, it remains unclear whether normal urothelial cells intrinsically possess a hybrid mesenchymal-like epithelial state. We analyzed scRNA-seq data of EPCAM+ urothelial cells from both mouse and human urothelium. Here, we identified and characterized a rare population of mesenchymal-like urothelial cells, termed M-cells, representing approximately 1–3% of urothelial cells. Vimentin-positive cells were evaluated by immunostaining to determine their distribution of M-cells in normal urothelial layers. M-cells are enriched within the basal layer but are present across all urothelial compartments. M-cells co-express epithelial markers with mesenchymal and stemness genes and engage stem cell-associated transcriptional regulators. Lineage tracing with the Upk2-Cre ; mT/mG reporter mice confirmed their urothelial origin, excluding a fibroblast lineage. M-cells exhibit high transcriptional plasticity between basal cells and intermediate cells. In addition, we identified a 16-gene transcriptional signature uniquely expressed in M-cells but absent in fibroblasts. RNA deconvolution of MB49 tumors demonstrated strong enrichment of M-cell signature, suggesting that MB49 tumors are more likely to represent sarcomatoid urothelial carcinoma rather than fibroblast-derived sarcoma. The clinical relevance of the M-cell state was validated in primary human sarcomatoid bladder cancer tumors and their corresponding patient-derived xenografts. Together, these findings establish rare and transcriptionally unique M-cells within the normal urothelium as a novel highly plastic population with clinical implications for both mouse and human sarcomatoid urothelial carcinoma.
- Open Access
- 1 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Nuclear-specific reductive carboxylation of alpha-ketoglutarate fuels histone acetylation to induce chromatin accessibility and gene activation
Mitochondria remain at the core of cell metabolism, whereas the nucleus integrates cellular and environmental signals to activate genes. However, the mechanisms that directly link cellular metabolism to gene regulation are not well understood. Here we show, a metabolic pathway in the nucleus controls acetylation of histones by nuclear localization of mitochondrial enzymes aconitase (ACO2) and isocitrate dehydrogenase (IDH2). Metabolic tracing studies show that IDH2 and ACO2 catalyze reductive carboxylation of α-ketoglutarate to rapidly synthesize citrate to increase nuclear acetyl-CoA pool. Genetic and proteomic analyses reveal nuclear IDH2 and ACO2 form a complex with KAT2A/GCN5 for acetylation of histones to increase chromatin accessibility and activation of proliferative genes. Robust nuclear expressions of ACO2 and IDH2 drive aggressive tumors indicating the tumorigenic potential of IDH2-ACO2-KAT2A axis. Altogether, our work reveals a paradigm coupling a nuclear metabolic pathway with histone acetylation to control of gene expression that accentuates hyperproliferative phenotype in tumors.
- 1 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNuclear-specific reductive carboxylation of alpha-ketoglutarate fuels histone acetylation to induce chromatin accessibility and gene activation
Mitochondria remain at the core of cell metabolism, whereas the nucleus integrates cellular and environmental signals to activate genes. However, the mechanisms that directly link cellular metabolism to gene regulation are not well understood. Here we show, a metabolic pathway in the nucleus controls acetylation of histones by nuclear localization of mitochondrial enzymes aconitase (ACO2) and isocitrate dehydrogenase (IDH2). Metabolic tracing studies show that IDH2 and ACO2 catalyze reductive carboxylation of α-ketoglutarate to rapidly synthesize citrate to increase nuclear acetyl-CoA pool. Genetic and proteomic analyses reveal nuclear IDH2 and ACO2 form a complex with KAT2A/GCN5 for acetylation of histones to increase chromatin accessibility and activation of proliferative genes. Robust nuclear expressions of ACO2 and IDH2 drive aggressive tumors indicating the tumorigenic potential of IDH2-ACO2-KAT2A axis. Altogether, our work reveals a paradigm coupling a nuclear metabolic pathway with histone acetylation to control of gene expression that accentuates hyperproliferative phenotype in tumors.
- Open Access
STAG2 Maintains Chromatin Compartmentalization and Represses Regulatory Element Contact to Promote Oncogenic Signaling in Muscle Invasive Bladder Cancer
Contrary to other cancer types, stromal antigen 2 (STAG2) expression is associated with shorter survival and an invasive phenotype in muscle invasive bladder cancer (MIBC). As a cohesin complex component, STAG2 regulates genome organization and cell type-specific transcription, yet its mechanistic role in MIBC remains unclear. Here, we uncover mechanisms through which STAG2 coordinates chromatin architecture and gene regulation in MIBC. Modulation of STAG2 rewired chromatin architecture, altering chromatin contacts and compartmentalization, increasing promoter-enhancer interactions, and reducing short-ranged chromatin loops. At specific gene loci, we discovered that STAG2 has context-specific activating and repressive regulatory functions. At the STAG2-activated gene ABCA1, STAG2 maintained A-compartment chromatin and high levels of promoter acetylation, indicators of active transcription. STAG2 KO resulted in loss of promoter acetylation, a shift from A to B compartment chromatin, and increased occupancy of the co-repressor TRIM28, resulting in ABCA1 downregulation and diminished invasive potential. Conversely, at the STAG2-repressed gene SPOCK3, STAG2 KO resulted in B to A compartment switching, aberrant formation of chromatin loops, and SPOCK3 upregulation. Treatment with EZH2 inhibitor tazemetostat augmented STAG2-KO induced SPOCK3 upregulation, suggesting a collaborative role of STAG2 and EZH2 in repressing Polycomb Repressive Complex 2 (PRC2) target genes. Altogether, our results indicate that STAG2 plays a multifaceted role in regulating gene expression in bladder cancer that is dictated by the epigenetic and chromatin landscape of the cells. These findings identify STAG2-dependent vulnerabilities and provide a rationale for therapeutic targeting of chromatin regulators in MIBC.
Open AccessSTAG2 Maintains Chromatin Compartmentalization and Represses Regulatory Element Contact to Promote Oncogenic Signaling in Muscle Invasive Bladder Cancer
Contrary to other cancer types, stromal antigen 2 (STAG2) expression is associated with shorter survival and an invasive phenotype in muscle invasive bladder cancer (MIBC). As a cohesin complex component, STAG2 regulates genome organization and cell type-specific transcription, yet its mechanistic role in MIBC remains unclear. Here, we uncover mechanisms through which STAG2 coordinates chromatin architecture and gene regulation in MIBC. Modulation of STAG2 rewired chromatin architecture, altering chromatin contacts and compartmentalization, increasing promoter-enhancer interactions, and reducing short-ranged chromatin loops. At specific gene loci, we discovered that STAG2 has context-specific activating and repressive regulatory functions. At the STAG2-activated gene ABCA1, STAG2 maintained A-compartment chromatin and high levels of promoter acetylation, indicators of active transcription. STAG2 KO resulted in loss of promoter acetylation, a shift from A to B compartment chromatin, and increased occupancy of the co-repressor TRIM28, resulting in ABCA1 downregulation and diminished invasive potential. Conversely, at the STAG2-repressed gene SPOCK3, STAG2 KO resulted in B to A compartment switching, aberrant formation of chromatin loops, and SPOCK3 upregulation. Treatment with EZH2 inhibitor tazemetostat augmented STAG2-KO induced SPOCK3 upregulation, suggesting a collaborative role of STAG2 and EZH2 in repressing Polycomb Repressive Complex 2 (PRC2) target genes. Altogether, our results indicate that STAG2 plays a multifaceted role in regulating gene expression in bladder cancer that is dictated by the epigenetic and chromatin landscape of the cells. These findings identify STAG2-dependent vulnerabilities and provide a rationale for therapeutic targeting of chromatin regulators in MIBC.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Characterization of Ezh2 deficient GEMMs
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Characterization of Ezh2 deficient GEMMs
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
AR genome binding patterns and transcriptional effects are altered in Ezh2 deficient PrCa
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
AR genome binding patterns and transcriptional effects are altered in Ezh2 deficient PrCa
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Genes whose expression is correlated with cancer plasticity
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Genes whose expression is correlated with cancer plasticity
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Phenotype of PrCa lineage variants developing in mice
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Phenotype of PrCa lineage variants developing in mice
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Chromatin remodeling in PrCa lineage variants
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Chromatin remodeling in PrCa lineage variants
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
PCR primers used in the experiments described
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
PCR primers used in the experiments described